Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment

Na Li; Ruonan Li; Qiongqiong Ma; Xiaoqi Zhang; Wenxuan Ma; Yi Wang; Baoxin Duan; Kailu Yang; Dongping Zhang; Jiashuo Zhang; Manping Gu; Yaxing Wu; Jiajin Sun; Huawei Wang; Anqi Li; Fuquan Chen; Yiyang Bai; Yujie Tian; Xin Li; Yingbin Yan; Wei Wang; Hongkai Zhang; Yuan Wang

doi:10.1002/ctm2.70428

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (8) : e70428 DOI: 10.1002/ctm2.70428

LETTER TO THE JOURNAL

Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment

Author information +

History +

PDF

Cite this article

Download citation ▾

Na Li, Ruonan Li, Qiongqiong Ma, Xiaoqi Zhang, Wenxuan Ma, Yi Wang, Baoxin Duan, Kailu Yang, Dongping Zhang, Jiashuo Zhang, Manping Gu, Yaxing Wu, Jiajin Sun, Huawei Wang, Anqi Li, Fuquan Chen, Yiyang Bai, Yujie Tian, Xin Li, Yingbin Yan, Wei Wang, Hongkai Zhang, Yuan Wang. Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment. Clinical and Translational Medicine, 2025, 15(8): e70428 DOI:10.1002/ctm2.70428

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021; 219: 107709.

[2]	Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020; 71: 47-58.

[3]	Knorr DA, Dahan R, Ravetch JV. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A. 2018; 115: 11048-11053.

[4]	White AL, Chan HTC, Roghanian A, et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011; 187: 1754-1763.

[5]	Sum E, Rapp M, Dürr H, et al. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J Immunother Cancer. 2022; 10: e003264.

[6]	Ishihara J, Ishihara A, Potin L, et al. Improving efficacy and safety of agonistic anti-CD40 antibody through extracellular matrix affinity. Mol Cancer Ther. 2018; 17: 2399-2411.

[7]	Traxlmayr MW, Lobner E, Antes B, et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. Protein Eng Design Select. 2013; 26: 255-265.

[8]	Orlova A, Magnusson M, Eriksson TLJ, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66: 4339-4348.

[9]	Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001; 276: 6591-6604.

[10]	Lobner E, Humm A-S, Göritzer K, et al. Fcab-HER2 interaction: a Ménage à Trois. Lessons from X-ray and solution studies. Structure. 2017; 25: 878-889.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.